"Pharmaxis & the Cystic Fybrosis Market"

Dr Robertson has more than 20 years experience in drug discovery and product development with leading pharmaceutical companies, including eight years with Wellcome plc in London and with Australian companies Faulding Ltd and Amrad Ltd.  He has assisted many early-stage pharmaceutical companies in their start-up and development and was the inaugural Chief Executive Officer and Managing Director of Pharmaxis.  Alan has been leading Pharmaxis since December 1999 and has been instrumental in building the company to its present position.  Pharmaxis listed on the ASX in 2003 and on the NASDAQ in 2005.  Alan has a PhD in synthetic organic chemistry from the University of Glasgow and has extensive practical understanding of the pharmaceutical industry.  Alan is the inventor of the migraine therapeutic Zomig, which is marketed worldwide by AstraZeneca.

Alan is a non-executive Director of Patrys Lyd, and Advent Pty Ltd and a Member of the Scientific Advisory Board of Xenome Ltd and the Australian Cancer Research Foundation Drug Discovery Centre for Childhood Cancer.